MAIA Biotechnology Launches New Lung Cancer Therapy with $34.1 Billion Market Potential
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 22 hour ago0mins
- New Treatment Direction: MAIA Biotechnology's ateganosine is considered the first telomere-targeting drug for non-small cell lung cancer (NSCLC) patients, aiming to address the treatment gap for those without actionable mutations, which could significantly improve prognosis for this underserved population.
- Market Size Growth: The global NSCLC market is estimated at $34.1 billion in 2024 and is projected to nearly double to $68.8 billion by 2033, highlighting the substantial commercial opportunity for this new therapy.
- FDA Fast Track Designation: The drug has received Fast Track Designation from the U.S. FDA, indicating its potential importance in treating patients resistant to immunotherapy and chemotherapy, which could position it as a key option in future treatments.
- Multiple Market Opportunities: Beyond lung cancer, ateganosine has also received Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer, further strengthening MAIA's market position and long-term growth potential in oncology.
MAIA.A
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on MAIA
About MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is ateganosine's primary target in non-small cell lung cancer treatment?
Why is ateganosine considered a breakthrough for NSCLC patients without actionable mutations?
How might the NSCLC market value change by 2033 with ateganosine's success?
What could be the financial impact of ateganosine's FDA Fast Track Designation?